Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program

Details

Basic Details

Date

Monday, May 13, 2013

Type

Publication

Medical Product

bupropion

smoking cessation drug

varenicline tartrate

Health Outcome(s)

acute coronary occlusion without myocardial infarction

acute myocardial infarction (AMI)

cardiovascular outcome

intermediate coronary syndrome

unstable angina

Description

This article describes a Mini-Sentinel modular program-based one-time rapid assessment of the risk of a composite cardiovascular outcome associated with new use of smoking cessation drugs, including varenicline and bupropion. Modular programs are adaptable standardized programs.

Materials

JAMA Internal Medicine, Volume 173, Issue 9, May 2013, Pages 817-819, DOI: 10.1001/jamainternmed.2013.3004

Additional Information

Information

Time Period

2006-2011

Population / Cohort

All individuals 18 years of age or older

Data Source(s)

Mini-Sentinel Distributed Database (MSDD)

Contributors

Author(s)

Sengwee Toh ScD; Meghan A. Baker MD, ScD; Jeffrey S. Brown PhD; Cynthia Kornegay PhD; Richard Platt MD, MS

Corresponding Author

S. Toh, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, USA. E-mail: darren_toh@harvardpilgrim.org